Another Pfizer bid for AstraZeneca? Investors weigh in

Stacy Lawrence

A higher price could get a deal done between and if British regulators play along, but aren't convinced that would be a particularly good outcome for either company. The two pharmas aren't far apart on price, and any renewal of negotiations could come as early as August.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS